RE:SNUS merges with private firm, OncoGenex Technologies:
OncoGenex is pursuing cancer treatments using antisense licensed from Isis Pharmaceuticals. LLY is also developing antisense cancer treatments based on Isis IP.
First generation antisense had a lugubrious track record with regard to cancer (and virtually everything else.) It seems noteworthy that LLY is still aboard after the Affinitak debacle.